GS
65
16
AMT
30
2
GT
43
2
CAH
44
7
AMAT
33
3
NSC
33
6
CMS
57
2
PRU
39
3
PEP
33
4
CF
47
5
CMCSA
49
3
AMG
33
-11
AMP
43
2
TXT
46
4
OI
23
3
DIS
70
2
SYF
78
7
UPS
51
6
IPG
43
3
L
54
5
GS
65
16
AMT
30
2
GT
43
2
CAH
44
7
AMAT
33
3
NSC
33
6
CMS
57
2
PRU
39
3
PEP
33
4
CF
47
5
CMCSA
49
3
AMG
33
-11
AMP
43
2
TXT
46
4
OI
23
3
DIS
70
2
SYF
78
7
UPS
51
6
IPG
43
3
L
54
5
Financhill
Back

Theravance Biopharma 10K Form

Buy
51

TBPH
Theravance Biopharma

Last Price:
$9.62
Seasonality Move:
0.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TBPH News And Ratings

See the #1 stock for the next 7 days that we like better than TBPH

TBPH Financial Statistics

Sales & Book Value

Annual Sales: $57.4M
Cash Flow: $-5.2M
Price / Cash Flow: 0
Annual Sales: $3.78
Price / Book: 2.54

Profitability

EPS (TTM): -1.01000
Net Income (TTM): $-49.4M
Gross Margin: $71.9M
Return on Equity: -23.68%
Return on Assets: -13.1%

Theravance Biopharma Earnings Forecast

Key Theravance Biopharma Financial Ratios

  • The Gross Profit Margin over the past 9 years for TBPH is 100.00%.
  • The Selling, General & Administrative Expenses for TBPH have been equal to 122.07% of Gross Profit Margin.
  • The Research & Development expenses have been 70.74% of Revenue.
  • The Interest Expense is -4.26% of Operating Income.
  • The Net Earning history of TBPH is -96.11% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 5 years.

Theravance Biopharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TBPH
CUSIP: G8807B
Website: theravance.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.97
Quick Ratio: 4.62

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 9.95

TBPH Technical Analysis vs Fundamental Analysis

Buy
51
Theravance Biopharma (TBPH) is a Buy

Is Theravance Biopharma a Buy or a Sell?